Company intelligence / Profile preview
Mucosis B.V.
Groningen, Netherlands
- Ownership
- Private
- Development stage
- Other
01
Overview
Mucosis’s lead product SynGEM®, a stabilized recombinant intranasal vaccine against RSV, entered Phase I human proof-of-concept studies in 2016 at Imperial College London. The trial was supported by €3.4 million from the Wellcome Trust and involved 36 volunteers to assess antibody production. The company has also developed PneuGEM® (pneumococcus) and FluGEM® (influenza), with FluGEM® serving as a successful proof of concept in humans for the Mimopath platform[2][5]. No recent late-stage results are available.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Needle-free vaccines (mucosal vaccines)recombinant subunit vaccinesbacterium-like particles (BLPs)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
US National Institutes of Health (NIH)Changchun BCHT Biotechnology Co. (China)Utrecht UniversityNetherlands Enterprise Agency
Beyond the preview
Go deeper on Mucosis B.V..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mucosis B.V..